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Abstract: Cerebrospinal fluid (CSF) is a readily reachable body fluid that is reflective of the
underlying pathological state of the central nervous system (CNS). Hence it has been targeted
for biomarker discovery for a variety of neurological disorders. CSF is also the major route for
seeding metastases of CNS malignancies and its analysis could be informative for diagnosis and risk
stratification of brain cancers. Recently, modern high-throughput, microRNAs (miRNAs) measuring
technology has enabled sensitive detection of distinct miRNAs that are bio-chemicallystable in
the CSF and can distinguish between different types of CNS cancers. Owing to the fact that a
CSF specimen can be obtained with relative ease, analysis of CSF miRNAs could be a promising
contribution to clinical practice. In this review, we examine the current scientific knowledge on
tumor associated CSF miRNAs that could guide diagnosis of different brain cancer types, or could be
helpful in predicting disease progression and therapy response. Finally, we highlight their potential
applications clinically as biomarkers and discuss limitations.
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1. Background
The most frequently occurring brain malignancies in adults are metastatic brain cancers that have
spread to the central nervous system (CNS) from other body parts, followed by glioblastomas [1,2]
while the most common brain tumors in children are astrocytomas, medulloblastomas and
ependymomas [3] (Figure 1). The current diagnostic tools for brain cancer, including clinical
manifestations, neuroimaging Magnetic resonance imaging (MRI) and computed tomography
(CT) and histology, although indispensable, have limitations and are used relatively late in the
pathogenesis. Clinical signs and symptoms are often subtle and unspecific while sensitivity and
specificity of neuroimaging differ widely with the type of cancer and location [4]. Histology remains
the gold standard analysis that is most frequently used for achieving diagnosis, yet tumor biopsy is
an invasive method, which is associated with the risk of brain hemorrhage and neurologic damage. In
addition some brain-lesions are not surgically accessible and accordingly are not amenable to biopsy.
Hence it becomes a clinical imperative to define biological markers that are sensitive enough to aid in
the detection of brain malignancy, preferably at an early stage.
Several blood tumor markers are presently used for a wide range of cancer types including
cancer antigen (CA)-125, α-fetoprotein (AFP), CA15-3/CA27.29 and prostate-specific antigen (PSA)
for ovarian, liver, breast and prostate cancer, respectively, as well as β-2-microglobulin (B2M)
for chronic lymphocytic leukemia, β-human chorionic gonadotropin (β-hCG) for testicular cancer;
CA19-9 for gastric, gall bladder and pancreatic cancer; urokinase plasminogen activator (uPA) and
plasminogen activator inhibitor (PAI-1) for breast cancer; and thyroglobulin for thyroid cancer [4,5].
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Figure 1. Main types and locations of primary brain tumors: (1) Gliomas, (2) Supratentorial 
Ependymoma, (3) Infratentorial Ependymoma, (4) Astrocytomas, (5) Medulloblastomas,  
(6) Meningioma, (7) Craniopharyngioma, (8) Pituitary tumors, and (9) Schwamannomas. 
However, one of the challenges that contributes to the paucity of biomarkers in the serum of 
CNS malignancies is the blood–brain barrier, which is thought to prevent the release of 
tumor-specific molecules into the circulation. The Cerebrospinal fluid (CSF) has thus been 
investigated in the search for brain tumor markers. 
Profiling of circulating miRNA expression in the CSF has linked specific miRNAs to CNS 
malignancies. They can distinguish between different types of brain cancers, reflect disease activity 
and could be associated with drug resistance [1,2,6,7]. Since deregulated miRNA expression is an 
early event in tumorigenesis, their presence in CSF may represent a gold mine of biomarkers for 
early brain cancer detection, which can contribute greatly to treatment success [8–10]. Hence great 
efforts have been made in conducting research evaluating their diagnostic value in CNS cancers, 
reviewed in [10]. 
In this review, we provide a short overview on the diagnostic significance of miRNA circulating 
in CSF of patients with brain cancer disease and discuss limitations and challenges. 
2. miRNAs Circulating in Body Fluids 
While miRNAs are found mainly inside cells, a considerable number of miRNAs have recently 
been discovered circulating in a stable, extracellular form—in various body fluids, including plasma, 
serum, CSF, urine, and saliva [11–15] (Figure 2). However, the origin and the function of these 
circulating miRNAs (c-miRNAs) are not well understood. Cancer cells in culture have also been 
reported to export miRNAs into the extracellular environment [16–19]. There have been relatively 
few published reports, including ours, on the isolation of miRNAs from cell-conditioned media 
[17,20–22]. However, the function of such secreted miRNAs remains essentially unclear. Because of 
their stability and easy detection in body fluids, an increasing number of studies have focused on 
c-miRNAs potential as non-invasive biomarkers and as therapeutic targets or tools for cancers. 
Several reports have described that deregulated c-miRNAs in body fluids are closely associated with 
the clinical course of various brain lesions including cancer [23–30]. For example, but not limited to, 
Lawrie et al. [31] reported that serum level of miR-21 is reversely associated with relapse-free 
survival in patients with diffuse large B-cell lymphoma. While the levels of miR-486, miR-30d, 
miR-1, and miR-499 were significantly associated with overall survival of non-small-cell lung cancer 
[32]. In another publication, it was reported that levels of miR-141 in serum could distinguish 
between patients with prostate cancer and healthy subjects [14]. Ng et al. [33] showed that miR-92 
can detect colon cancer in plasma samples. Moreover, Yamamoto et al. [34] reported that patients 
with hepatocellular carcinoma have high serum levels of miR-500, which were significantly reduced 
after surgery and returned to normal levels. While Wong et al. [35] showed that plasma level of 
miR-184 is much higher in cancer patients with early and advanced squamous cell carcinoma of the 
tongue than in normal individuals and is reduced in patients after the surgical removal of the 
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However, one of the challenges that contributes to the paucity of biomarkers in the serum of
CNS malignancies is the blood–brain barrier, which is thought to prevent the release of tumor-specific
molecules into the circulation. The Cerebrospinal fluid (CSF) has thus been investigated in the search
for brain tumor markers.
Profiling of circulating miRNA expression in the CSF has linked specific miRNAs to CNS
malignancies. They can distinguish between different types of brain cancers, reflect disease activity
and could be associated with drug resistance [1,2,6,7]. Since deregulated miRNA expression is an
early event in tumorigenesis, their presence in CSF may represent a gold mine of biomarkers for early
brain cancer detection, which can contribute greatly to treatment success [8–10]. Hence great efforts
have been made in conducting research evaluating their diagnostic value in CNS cancers, reviewed
in [10].
In this review, we provide a short overview on the diagnostic significance of miRNA circulating
in CSF of patients with brain cancer disease and discuss limitations and challenges.
2. miRNAs Circulating in Body Fluids
While miRNAs are found mainly inside cells, a considerable number of miRNAs have recently
been discovered circulating in a stable, extracellular form—in various body fluids, including plasma,
serum, CSF, urine, and saliva [11–15] (Figure 2). However, the origin and the function of these
circulating miRNAs (c-miRNAs) are not well understood. Cancer cells in culture have also been
reported to export miRNAs into the extracellular environment [16–19]. There have been relatively few
published reports, including ours, on the isolation of miRNAs from cell-conditioned media [17,20–22].
However, the function of such secreted miRNAs remains essentially unclear. Because of their stability
and easy detection in body fluids, an increasing number of studies have focused on c-miRNAs
potential as non-invasive biomarkers and as therapeutic targets or tools for cancers. Several
reports have described that deregulated c-miRNAs in body fluids are closely associated with the
clinical course of various brain lesions including cancer [23–30]. For example, but not limited to,
Lawrie et al. [31] reported that serum level of miR-21 is reversely associated with relapse-free survival
in patients with diffuse large B-cell lymphoma. While the levels of miR-486, miR-30d, miR-1, and
miR-499 were significantly associated with overall survival of non-small-cell lung cancer [32]. In
another publication, it was reported that levels of miR-141 in serum could distinguish between
patients with prostate cancer and healthy subjects [14]. Ng et al. [33] showed that miR-92 can
detect colon cancer in plasma samples. Moreover, Yamamoto et al. [34] reported that patients with
hepatocellular carcinoma have high serum levels of miR-500, which were significantly reduced after
surgery and returned to normal levels. While Wong et al. [35] showed that plasma level of miR-184
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is much higher in cancer patients with early and advanced squamous cell carcinoma of the tongue
than in normal individuals and is reduced in patients after the surgical removal of the primary tumor
reviewed in [16]. The significant differences between c-miRNA expression profiles in body fluids of
cancer patients and those of healthy individuals and importantly the association of c-miRNAs with
the clinical course of the disease has raised the possibility that they may serve as a novel minimally
invasive and sensitive approach to detect cancer in its early stages [2,24,25].
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Figure 2. Time line depicting the discoveries of body fluids’ miRNAs and their contribution to cancer 
detection. CSF: Cerebrospinal fluid. * [36–38]; ** Lung [39], Brest [40], Ovarian [41], Cervical [42], 
Prostate [43], Renal [44], Rectal [45], Gastric [46], Liver [47], Pancreatic [48], Oesophageal [49], Head 
and neck [50], Thyroid [51], Skin [52], laryngeal [53], Lymphomas [54], Leukaemia [55] and Brain 
cancer [56–59]; *** Serum [11,31], Plasma [14], CSF [12]; **** Glioma [2,60,61], PCNSL [29,61,62], 
Medulloblastoma [22,61], Brain metastasis [2,61]. 
3. Cerebrospinal Fluid (CSF) as Diagnostic Window for the Pathological State of the Central 
Nervous System (CNS) 
3.1. CSF Characteristics 
CSF is formed mainly in the ventricular choroid plexus and distributed within the ventricular 
system and subarachnoid space. It contains 15 to 45 mg/dL protein, 50–80 mg/dL glucose and  
0–5 mononuclear white blood cells/mL and serves as a medium for the nutrients delivery to the CNS 
as well as carrying away waste. Because CSF bathes the CNS and comes into close contact with any 
pathological brain tissue, it is considered an ideal source of molecules related to brain cancers as it 
can be accessed readily for diagnosis as well as for longitudinal disease monitoring during therapy. 
Approximately up to 20 mL of CSF is usually collected for testing through a lumbar puncture (spinal 
tap) where a needle is inserted, usually between the 3rd and 4th lumbar vertebrae. Such a laboratory 
smear poses only minimal risk to the patient. In a routine clinical setting, CSF analysis is widely used 
for diagnostic and prognostic purposes, and it provides critically important information for a 
number of neurological diseases [63,64]. 
3.2. CSF Analysis for Brain Cancer Markers Detection 
Cancer cells infiltrate the CSF either directly from primary CNS cancers through direct spread 
from tumors that are in close contact with the CSF or through blood brain barrier penetration from 
cancers that have spread to the CNS from other body parts [2]. CSF cytology, in which CSF is 
examined under a microscope to look for neoplastic cells (presence or absence) is currently 
considered the gold standard test for diagnosis, tumor staging, and therapy decisions in many types 
of cancer such as medulloblastoma, lymphoma, and metastatic carcinomas [65]. Although 
indispensable, this method bears neither quantification nor molecular analysis of tumor cells, lacks 
sensitivity and assignment to a particular tumor is often not possible [65–67]. 
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Approxi ately up to 20 L of CSF is usually collected for testing through a lu bar puncture (spinal
tap) here a needle is inserted, usually bet een the 3rd and 4th lu bar vertebrae. Such a laboratory
s ear poses only ini al risk to the patient. In a routine clinical setting, CSF analysis is idely used
for diagnostic and prognostic purposes, and it provides critically important information for a number
of neurological diseases [63,64].
3.2. CSF Analysis for Brain Cancer Markers Detection
Cancer cells infiltrate the CSF either directly from primary CNS cancers through direct spread
from tumors that are in close contact with the CSF or through blood brain barrier penetration from
cancers that have spread to the CNS from other body parts [2]. CSF cytology, in which CSF is
examined under a microscope to look for neoplastic cells (presence or absence) is currently considered
the gold standard test for diagnosis, tumor staging, and therapy decisions in many types of cancer
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such as medulloblastoma, lymphoma, and metastatic carcinomas [65]. Although indispensable,
this method bears neither quantification nor molecular analysis of tumor cells, lacks sensitivity and
assignment to a particular tumor is often not possible [65–67].
To maximize the chances of finding brain cancer markers in the CSF, it has been realized
that it is necessary to detect changes at the molecular level rather than waiting for a macroscopic
tumor to emerge [65]. Various methods and new technologies are being tested for in vitro
assessment of CSF looking for potential markers for CNS cancers including: proteochemical
and immunophenotypic studies by flow cytometry (that provides information about cell surface
protein expression), molecular genetic analyses of CSF [67], immunocytochemistry, immunoglobulin
heavy chain (IgH) rearrangement which analyzes the clonality of the antibodies being produced,
polymerase chain reaction, fluorescence in-situ hybridization (FISH), DNA single cell cytometry,
capillary electrophoresis and mass spectrometry reviewed in [4,65]. Proteomic profiling of CNS
malignancies has revealed that free immunoglobulin light chains and antithrombin III, a serine
protease inhibitor that is associated with neo-vascularization, are differentially expressed in some
brain cancers [68,69]. Levels of lactate dehydrogenase (LDH4 and LDH5), cell surface proteins such
as β2-microglobulin, CXC chemokines (CXCL13 and CXCL12), soluble CD27, vascular endothelial
growth factor, urokinase and tissue plasminogen activator have been evaluated in the CSF as
brain cancer markers [70–74], Table 1. However none of these markers have been clinically
validated [64]. On the other hand levels of conventional tumor markers (which are used to
monitor treatment and detect recurrence in serum of patients with various malignancies) such as
cancer antigen 125 (CA125), CA19-9, CA72-4, CA715-3, alpha-fetoprotein (AFP), Neuron-specific
Enolase (NSE), cytokeratin-19 fragment (CYFRA 21-1), Epidermal Growth Factor Receptor (EGFR)
and beta- human chorionic gonadotropin (β-hCG) β-human chorionic gonadotropin were tested
in the CSF of brain cancer patients. Elevated levels of such markers in the CSF but not
in serum were found to be relatively specific for some brain cancer [70–75]. Then again,
sensitivities and specificities have varied widely, reviewed in [4]. Loss of 1p and 19q and
mutant IDH1 (Isocitrate Dehydrogenase 1) as well as O6-methylguanin-DNA-methyltransferase
(MGMT) promoter methylation were detected in glioma patients, and efforts to locate these
aberrations in circulating tumor cells are ongoing [76,77]. Abnormality in CSF component
has in addition been reported in brain cancer cases. These abnormalities include increased leukocytes
(>4/mm3), elevated protein (>50 mg/dL), and decreased glucose (<60 mg/dL). Although indicative
of brain cancer these CSF abnormalities are nonspecific [29,78–80]. However, in general, the use of the
above-mentioned markers has been limited due to their poor sensitivity and specificity. Moreover,
there was no clear correlation with the type of cancer or response to treatment observed reviewed
in [4].
Table 1. Markers in body fluids that have potential application for brain cancer detection.
Marker Sample Type of Brain Cancer References
* AT III * CSF * CNS lymphoma [68,81,82]
EGFR CSF Brain metastases fromlung adenocarcinoma [83]
Pro-inflammatory (* IL-1β, IL-6, IL-8,
IL-12, * GM-and * TNF-α) and
anti-inflammatory cytokines (IL-4,
IL-10), and (* VEGF, * bFGF)
Blood Serum Glioblastoma [84]
* CYFRA 21-1, * NSE and * CEA CSF Meningeal carcinomas [85]
* CXCL13 plus interleukin 10 CSF CNS lymphoma [74]
* VEGF receptor 1 and 2 CSF Leukemia CNSmetastasis [86]
miR-21 and miR-15b CSF Glioblastoma [25]
miR-19, miR-21, and miR-92a CSF * PCNSL [25]
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Table 1. Cont.
Marker Sample Type of Brain Cancer References
miR-10b and miR-21 CSF Glioblastoma and brain Metastasis [2]
Members of miR-200
family CSF
Brain metastases from lung and breast
cancers [2]
miR 210 Serum Gliomas [81]
miRNA-205 Serum Glioma [87]
miR-21 CSF Glioma [60]
MiR-451, -711, -223 and
-125b CSF
Glioblastoma, medulloblastoma, brain
metastasis and lymphoma [61]
MiR-935 CSF Only brain metastasis [61]
* GFAP and * EGFR Serum Gliomas [88]
Interleukin-10 CSF PCNSL [89]
* PGD2 CSF Medulloblastoma [90]
* IgG levels CSF Cerebral low-grade lymphoma [91]
CXCL13 and CXCL12 CSF CNS lymphoma [92]
* MIC-1/* GDF15 CSF Glioblastoma [93]
Vascular endothelial
growth factor (VEGF)
and stromal cell derived
factor (SDF)-1
CSF Brain metastases from lung and breastcancers [94]
β-2 microglobulin CSF Myeloma of the central nervous system [94]
Apolipoprotein A-II CSF
Pediatric brain tumors (medulloblastoma ,
high-grade glioma, atypical rhabdoid
tumor, astrocytoma, plexus carcinoma and
anaplastic ependymoma, germ cell tumor)
[95]
VEGF CSF Leptomeningeal metastasis [96]
VEGF and serologic
(recoverin) CSF and serum Malignant glioma [97]
Mitochondrial DNA
mutations CSF Medulloblastoma [98]
c-kit CSF Germ cell tumors [99]
Human chorionic
gonadotropin (hCG) and
α-fetoprotein (AFP)
Serum and CSF Intracranial germ cell tumors [100]
Prostaglandin D
synthase (β-trace) CSF Meningeal hemangiopericytoma [101,102]
CD27 CSF CNS lymphoma [103]
β-hCG CSF and serum Brain metastases from gestationaltrophoblastic tumors [104]
* Abbreviations: Antithrombin III (A III), Cerebrospinal fluid (CSF), central nervous system (CNS),
Interleukin-1 beta (IL-1β), granulocyte macrophage-colony stimulating factor (GM-CSF), tumor necrosis
factor-alpha (TNF-α), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF),
cytokeratin-19 fragment (Cyfra 21-1), Neuron-specific Enolase (NSE), carcinoembryonic antigen (CEA),
chemoattractant, chemokine (C-X-C motif) ligand 13 (CXCL13), vascular endothelial growth factor (VEGF),
Primary central nervous system lymphoma (PCNSL), Glial fibrillary acidic protein (GFAP), Epidermal growth
factor receptor (EGFR), Prostaglandin-D2 synthase (PGD2), Immunoglobulin G (IgG), Macrophage inhibitory
cytokine-1 (MIC-1), Growth differentiation factor 15 (GDF15).
4. miRNAs as Potential Novel Candidates for Brain Cancer Markers in the CSF
Studying miRNAs as biomarkers in brain cancer tissue samples has created noticeable advances
in cancer research. However, a key downside of the tissue-based approach is the need for surgical
procedures in sample collection. Therefore, brain cancer biomarkers’ researchers have now turned
their attention to the analysis of miRNAs present in biological fluids including CSF, which can be
collected with minimal invasiveness and permit following the disease over time [4]. It has been
speculated that c-miRNAs detected in the CSF of brain cancer patients—that originate from brain
tumor cells—can be pro-tumorigenic [105]. They can transfer their oncogenic activity to recipient
target cells where they change their properties by influencing molecular events of cancer-related
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processes such as growth, invasion and drug resistance. This exchange of miRNAs between
primary tumors and target cells is an interesting and novel dimension to the regulation of a cell
phenotype [106] and may be exceptionally important in malignancies that have a tendency for
dissemination. It is possible that primary brain tumors with intra cranial dissemination property
or tumors that metastasize to the brain from distance cancers may release miRNAs in the CSF with
clinically relevant oncogenic signatures. Hence studying miRNAs circulating in CSF of brain tumor
patients may be used to decode the molecular features of the underlying malignancy as well as their
metastasis [10].
5. Diagnostic and Prognostic Value of CSF miRNAs in Brain Cancers
Diagnosis of CNS involvement in neoplastic diseases, including both primary and metastatic
cancers, is a major clinical intractability [4]. To date, no reliable biomarkers for the detection and
risk stratification of CNS cancer have been identified. Great efforts have been made during the past
decades in conducting research evaluating the diagnostic value of miRNAs in the CSF of patients
with CNS cancers. Using qRT-PCR, Baraniskin et al. [25,62] investigated the diagnostic value of
miRNAs that are expressed with significant levels in CSF samples from patients with gliomas. The
authors found that out of the six miRNAs (miR-21, miR-15b, miR-196b, miR-92a and miR-204) studied
miR-21 and miR-15b have the potential to function as novel biomarkers for the detection of gliomas.
Both miR-21 and miR-15b were specifically expressed in CSF samples from patients with gliomas
compared to control subjects Impressively, analysis of miR-15b and miR-21 in combined expression
increased diagnostic accuracy with 100% specificity and discriminated between glioma patients and
controls including those with carcinomatous brain metastases and primary CNS lymphoma [25,62].
In a study by Teplyuk and colleagues [2], the authors examined miRNAs in the CSF of patients
with metastatic brain cancers, patients with glioblastoma multiforme (GBM), and non-neoplastic
controls. They reported that profiling miRNAs in CSF of these patients allowed the discrimination
between glioblastoma and metastatic brain tumors and reflects disease activity. Combined analysis
of a group of seven cancer related miRNAs, using q-RT-PCR, enabled discrimination between GBM
and metastatic brain cancers with more than 90% accuracy, suggesting that the presence of specific
c-miRNAs circulating in the CSF of brain tumor patients could be indicators of cancer presence.
miRNA-21 and miR-10b expression levels were significantly increased only in brain tumor lesions
(in patients with GBM or brain metastases) compared to non-neoplastic conditions, while members
of the miR-200 family were found solely in CSF of patients with brain metastases hence they could be
used to discriminate between glioblastoma and metastatic brain tumors, an important consideration
for cancer treatment. Furthermore, they showed that disease burden and treatment response can be
monitored over several months by longitudinal miRNA profiles of miR-10b, miR-21 and miR-200
in the CSF of brain tumor patients [2]. Given that GBM is the deadliest glioma with a median
survival of only 14 months despite the recent advances in intensive therapeutic strategies [58] and
that approximately one-third of cancer patients will develop brain metastases, more efforts were
applied to study whether specific CSF miRNA profile can be generated to evaluate gliomas prognosis.
In this setting, in a recent publication Shi and colleagues examined CSF from seventy patients with
recurrent glioma for the levels of cancer-related miRNAs, and evaluated the values for prognosis. The
authors reported that the CSF miR-21 circulating in the CSF levels is a promising indicator for glioma
diagnosis and prognosis, and can predict tumor recurrence or metastasis. Their results particularly
demonstrated that miRNA-21 expression in the CSF is associated with poor prognosis and tumor
recurrence of glioma patients [60].
Primary central nervous system lymphoma (PCNSL) is another highly aggressive tumor that
can lead to quick death if not diagnosed in time. The diagnosis of PCNSL can present a diagnostic
challenge. It relies on histopathology of brain biopsies to the same extent as most brain tumors,
while non-invasive tests to detect early tumor legions with sufficient diagnostic accuracy are not
available yet. In an earlier work, Baraniskin et al. demonstrated the presence of notably stable
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miRNAs in the CSF of PCNSL patients. The group identified specific miRNAs that are expressed
with significant levels in the CSF of patients with PCNSL compared to control. Using candidate
approach and miRNA quantification by qRT-PCR, the group discovered that miR-19, miR-21, and
miR-92a in CSF accurately discriminates patients with primary central nervous system lymphoma
from other neurologic disorders controls, indicating significant diagnostic value and increased
diagnostic accuracy with 95.7% sensitivity and 96.7% specificity [25,62,67]. On the same theme,
Scott et al. conducted a review of the literature on CNS lymphoma diagnosis (1966 to October 2011)
and extracted data regarding the usefulness of CSF cytology in the diagnosis of CNS lymphoma.
The authors reported low sensitivity for CSF cytology (2%–32%), which is increased when combined
with flow cytometry. Studying β2-microglobulin, and immunoglobulin heavy chain rearrangement
as well as lactate dehydrogenase isozyme 5 in the CSF has improved CSF cytology sensitivity but
not specificity. Interestingly, miRNA analysis has more than 95% specificity in the diagnosis of CNS
lymphoma [29].
Medulloblastoma (MB) is the most common malignant brain tumor in children. It includes
various subtypes with group 3 and 4 subtypes being clinically distinct with regard to metastasis
and prognosis, which may also manifest in a difference in their miRNA spectra. The presence and
biological role of ex-miRNAs in MBs was unknown until our lab recently examined the existence
of ex-miRNAs in MB extracellular environment and showed that the MB cells release miRNAs
in their spent culture medium. We used microarray analysis to unveil the identity and level of
expression of key miRNAs excreted in culture-medium of three cell lines representing different
MB subtypes, D341 and D283 (metastasis-related group 3 and group 4 MB subtypes) [107] and
DAOY (sonic hedgehog-related). More than one thousand secreted miRNAs were identified in
the culture medium in each of the MB cell lines tested. Among them a panel of miRNAs was
specific to the culture medium of metastasis-related cell lines which represents the aggressive group
3 and 4 MB subtypes. 60 miRNAs were overexpressed and 52 underrepresented compared to
DAOY culture medium. Interestingly, three metastasis-associated miRNAs (miR-1290, miR-125a, and
miR-125b) were over-represented in culture-medium of metastasis-related MB cell lines and found to
be significantly enriched in the CSF of the MB patient [22]. Although more samples are required
to fully verify these results, our work presented the first evidence for the presence of miRNAs
excreted extracellularly by MB cells and raises the possibility that investigations using larger sets
of MB samples could lead in the near future to the discovery of CSF-derived miRNA markers, with
diagnostic and prognostic significance and hopefully also with therapeutic potential.
In an elegant work by Wei and colleagues [108], the authors conducted systematic meta-analysis
searching different electronic databases and sources for relevant articles on the topic “the diagnostic
value of miRNAs for CNS cancers”. In this meta-analysis, a total of 299 CNS cancer patients and
418 controls were analyzed within 23 studies. Thirteen out of the 23 studies investigated miRNAs
for the detection of glioma and 10 studies for PCNSL diagnosis. In all studies, levels of miRNAs
expression were analyzed by qRT-PCR in patients CSF and blood in order to compare blood versus
CSF based miRNAs assays sensitivity for the diagnosis of CNS cancers. miRNAs in CSF showed
higher levels in sensitivity of CNS cancers detection suggesting a relatively high diagnostic accuracy
specially for PCNSL. By the end of the study, the authors concluded that CSF based miRNAs assays
may be suitable as biomarkers for detection of CNS cancers and could be considered more reliable for
clinical application [108].
At the time of writing this manuscript, Drusco et al. [61] analyzed 82 CFS samples from
neoplastic and non-diseased patients (normal, benign, glioblastoma, medulloblastoma, metastasis
and lymphoma) by Nanostring technique to identify a CSF microRNA signature that could
differentiate among CNS malignancies. The authors found that miR-451, -711, 935, -223 and -125b are
significantly differentially expressed in CSF of the tested groups and can differentiate between some
classes of CNS tumors tested. Their miRNA profile was further confirmed by RT-PCR and in situ
hybridization. Based on their results, the authors proposed a hypothetical diagnostic chart for CNS
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malignancies with a simple RT-PCR on patients’ CSF miRNAs. However, such miRNA signatures
needs to be tested on more samples with additional pathology and prognostic classes to determine
differentiating ranges of fold changes of expression among groups.
6. Considerations and Concerns about the Use of Circulating miRNAs as Biomarkers
An accurate non-invasive diagnostic test for brain tumors is unavailable; moreover, the current
diagnostic tools have limitations and under-diagnosis remains a major problem. Therefore, the goal
is to search for biomarkers that are able to detect early indicative sign of CNS neoplastic presence
in order to enable clinicians to react early with the most relevant therapy [109]. Early histological
diagnosis could be made possible by analysis for biomarkers specific to particular types of brain
tumor [110]. This would aid prognostication and help direct pre-operative management, such as
chemotherapy and radiotherapy. miRNAs circulating in the CSF of brain cancer patients offer a
dynamic and powerful approach to understanding the spectrum of brain cancers from the earliest
manifestations to the terminal stages. Their analysis provides insights about disease biology genetic
changes that might help to decode the molecular features of the underlying malignancy [87]. CSF
miRNAs specificity and chemical stability are clinically appealing as they are easily accessible by
minimally-invasive standard clinical methods [90,111]. Only small amounts of CSF samples are
usually required for the detection of miRNAs in the CSF, depending on which detection methods are
used. This offers the advantage of convenient repetitive monitoring of molecular events happening
in cancer in the response to treatment.
The rapid growth of miRNAs’ identification techniques and measuring technology, such as
qRT-PCR, next-generation sequencing or microarrays, gives us hope that the application of miRNAs
in CSF as technically feasible biomarkers will soon become clinically practicable. There are great
expectations that detecting miRNAs in CSF of brain tumor patients will achieve enhanced clinical
utility in the near future and will lead to the identification of individuals in the “preclinical” stages of
the illness. However, there are several concerns to consider before recommending the clinical use of
CSF miRNAs as markers for brain tumors.
The first concern is that little is known about the origin of c-miRNAs in the CSF of brain
tumor patients, what factors influence their level of expression and what impact this will have
on their specificity as biomarkers. The stability of circulating miRNAs in body fluids and culture
media of some cell lines suggests that they are likely packaged in some manner that protects
them against RNase digestion [89]. Studies have suggested that the majority of these miRNAs are
enclosed in lipid vesicles such as xosomes and microvesicles or in complexes with RNA-binding
proteins lines [18,112,113] (Figure 3). It has been hypothesized recently that such actively secreted
exosomal miRNAs are involved in intercellular communication [16–18]. However, it remains unclear
whether c-miRNAs are present in physiologically relevant amounts for cell-to-cell signaling. In
contrast, other studies suggest that most of the miRNAs in body fluids might be an offshoot of
dead/dying cells and they showed that such c-miRNAs are microvesicles free and independent from
exosomes [19,114]. In this scenario, c-miRNAs are bound to Argonaute (Ago) proteins as part of
RNA-induced silencing complex, which remain in extracellular space due to the high stability of the
miRNA/Ago complex [21]. However, the secretory mechanism and biological function, as well as
the meaning of the existence of extracellular miRNAs, remains largely unclear.
The ideal scenario is that CSF c-miRNAs are cancer related, originated from brain cancer cells
in the primary tumor and accordingly reflect the magnitude of the disease. This will lead to the
second concern that the chance is high that c-miRNAs in the CSF of brain tumor patients could be
expressed from or secreted by a mixture of different cell types in the tumor microenvironment, such
as inflammatory cells or other physiological response against the diseased tissue, jeopardizing their
specificity and their ability to honestly represent tumor cells [115]. The third concern is that levels
of miRNAs do not only depend on the production rate of cancer cell populations but can also be
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influenced by many other factors, including, cell degradation rates, clearance by liver and kidney,
infection, age, sex, treatment, epigenetic mechanisms, diet, lifestyle, and more [116].
Estimates of miRNA expression levels are known to be significantly affected by methods of
analysis and different miRNA profiles may be obtained depending on the sample analysis used.
However, there are no universally implemented guidelines for CSF sample preparation, miRNAs
extraction, measurements, normalization, or data analysis. On the contrary, there are various
platforms/techniques which exist, each with specific biases that can influence the results of certain
miRNA molecules expression measurements in the tested sample and may lead to foregone.Int. J. Mol. Sci. 2015, 16, pag –page 
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type) to be used to prepare cell-free miRNAs from CSF samples as residual cell debris can alter 
miRNA abundance [118]. Sample freezing condition (whether snap or slow freezing) and storage 
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Figure 3. Depiction of hypothetical origins and types of miRNAs in the CSF: Brain tumor-associated
miRNAs in the CSF could be actively released by brain tumor cells to the CSF either enclosed in
small membranous microvesicles (e.g., exosomes) or packaged with RNA-binding proteins, e.g.,
high-density lipoprotein (HDL) or Argonaute (Ago). A second possibility is that miRNAs are
passively released in the CSF by dead/dying cancer cells where it remains stably complexed to Ago
in the extracellular environment. In addition, freely circulating naked miRNAs (free of exosomes or
microvesicles) might be actively secreted from brain tumor cells or passively released from apoptotic
or necrotic cells. A third possibility is that a proportion of miRNAs are likely associated with detached
brain cancer cells (C.C) that are circulating in the CSF.
It is not surprising that there are often low correlations of results between different labs and,
hence, standardization is a challenge for the near future. The fourth concern is related to technical
challenges associated with miRNAs analysis.
6.1. Issues Associated with CSF Collection and Preparation
Collection of CSF is the first step in sample preparation; however, CSF is not an easy specimen to
obtain compared to other body fluids. Lumbar puncture (LP), although it poses a minimal risk to the
patient compared to biopsy, major and minor complications can occur even when standard infection
control measures and good techniques are used. These complications include: post-LP headache,
infection, bleeding, cerebral herniation and back pain.
Another worry is that CSF samples that are used as material for miRNA detection could be
contaminated with blood iatrogenically. Blood contamination of CSF would result in significant
increases in nucleated white blood cells (WBC) count that could contribute to miRNA content
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of the sample being analyzed. Skin cells can also contaminate CSF samples. In this situation,
skin contains abundant epithelial miRNAs that can bias results of miRNAs profiles. Method that
preserves the RNA expression profile during and after collection of CSF is another important factor
for accurate analysis of miRNA expression [117]. Centrifugation to remove debris or precipitates
from CSF samples prior to RNA extraction will alter miRNA profiles if it is not performed accurately.
Currently, there are no standardized centrifugation conditions (time, temperature, g-force, rotor type)
to be used to prepare cell-free miRNAs from CSF samples as residual cell debris can alter miRNA
abundance [118]. Sample freezing condition (whether snap or slow freezing) and storage time and
temperature should also be standardized.
6.2. Issues Associated with miRNA Isolation and Assessment
In general, working with RNA requires very special precautions to prevent degradation and or
contamination of the RNA sample. The practice for isolating miRNAs are, in principle, the same
as for isolation of total RNA, except that miRNA isolation protocols are often slightly modified to
retain the miRNAs. The first challenge is that CSF samples contain only small amounts of RNA and
extraction of sufficient miRNA amounts can be difficult [27]. Samples with low miRNA abundance
create challenges for downstream assays. Appropriate assessment of the quality and quantity of
extracted RNA is important for reproducibility and accuracy in miRNA-profiling studies. That will
bring us to the second challenge where quantification and measuring the amount of miRNAs isolated
from CSF samples is especially difficult due to the low concentration of RNA typically obtained
from these samples [117]. The low abundance of miRNA in CSF can hardly be determined using
standard simple methods for measurement of the RNA quantity and quality such as Nano-drop
or other spectrophotometers. Hence, an alternative multifaceted way to assess the yield and RNA
integrity has to be used. In this case, automated capillary electrophoresis instruments could be
used [26,37]. Finally, in addition to low miRNA concentration, samples are likely to contain high
levels of enzyme inhibitors that might affect the efficiency of the reverse transcription and choosing a
purification method that minimizes the effect of such inhibitors is still a great challenge.
6.3. Issues Associated with miRNA-Profiling/Detection Methods
Three major approaches are currently used for miRNAs detection in the CSF: qRT-PCR,
hybridization-based methods, such as DNA microarrays, and high-throughput sequencing
(RNA-seq). qRT-PCR assays are among the most frequently used high-throughput RT-PCR platforms
for miRNA detection. The attractive aspect of this approach is the ease of incorporation into the
workflow for laboratories that are familiar with real-time PCR. However, commercial assays that are
commonly used for miRNA detection use a different strategy to reverse transcribe mature miRNA
molecules and to amplify the cDNA, which might result in different detection biases. Another
obstacle in performing qRT-PCR is that reaction conditions may vary as well as sequence-specific
differences in primers [117].
6.4. Issues Associated with Data Normalization
Finally, data normalization (i.e., adjusting the data and removing technical variations across
samples that are not related to the biological changes under investigation) is tricky and can be
challenging. The optimal method to use for normalization is to identify stably expressed reference
genes or commonly expressed miRNAs in a given sample as normalization factor. However, no
constitutively expressed circulating miRNAs have been reported up till now in the CSF. Spiking
samples with RNA controls, applying reference miRNA such as miR-16 or miR-26a or other
non-coding RNA like U6 snRNA are some of the strategies used to standardize analysis, however
some of the larger small RNA species such as U6 RNA are present in extremely low concentrations
in body fluids. On the whole, the variability in normalization methods and analysis might be
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responsible for some of the discrepancies between miRNA-profiling studies and differences and
overlapped miRNAs signatures reported in the literature.
In summary, miRNA investigation in CSF samples as a potential marker for brain cancers is a
challenging procedure. The development of miRNAs as good biomarkers requires optimized and
standardized procedures for CSF sample collection handling and preparation, highly sensitive and
accurate miRNAs detection methods as well as reliable methods for data analysis [115].
7. Conclusions
Tumor-associated miRNAs circulating in the CSF have recently shown promise as diagnostic
indicators for some types of brain tumors owing to the substantial differences that have been
described between their expression profiles in healthy individuals and patients. Their chemical
stability in the CSF together with the recent advances in the sensitive mRNA measuring platforms
have generated demand to apply CSF miRNAs investigation procedure in clinical practice. However,
despite the promise, the available data on the suitability of the CSF miRNAs as diagnostic biomarkers
for brain cancer are still very limited and critical issues need to be clarified before making
recommendations for their clinical implementation. We need to have a better understanding about
the mechanisms by which tumor-specific miRNAs are produced in the CSF, what factors influence
their level of expression in the CSF of patients with brain tumors, and what impact will this have
on their specificity as diagnostic markers. More studies are certainly necessary to establish miRNAs
signatures for each brain cancer type and their different stages, and to determine which miRNAs
meaningfully reflect the dynamics of tumor response to therapy. Undoubtedly, CSF miRNAs are
a potential gold mine for identifying brain cancer biomarkers, however, much work remains to be
done to harness findings from scientific research to advance clinical applications.
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